BACKGROUND: EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque-type psoriasis as a part of totality of evidence gathered during the development of GP2015, an etanercept biosimilar. OBJECTIVE: To demonstrate equivalent efficacy and comparable safety and immunogenicity of GP2015 and the etanercept originator product (ETN, Enbrel® ) and evaluate effects of repeated switching between GP2015 and ETN. Results for efficacy, safety and immunogenicity during treatment period (TP) 2 (TP2) are presented pooling the two continued treatment arms (pooled continued) versus the two treatment arms with repeated switches (pooled switched). METHODS: Patients (n = 531) were randomized 1:1 to self-administer GP2015 or ETN twice-weekly subcutaneously during TP1. Patients with a ≥50% improvement in Psoriasis Area and Severity Index (PASI 50) at week 12 were re-randomized for TP2 to continue the same treatment at once-weekly dosing or to undergo three consecutive treatment switches between GP2015 and ETN until week 30. Patients continued the last-assigned treatment during TP2, until week 52. RESULTS: Mean (standard deviation [SD]) PASI scores at baseline were similar in patients who underwent multiple switches compared to those with continued treatments during TP2. During TP2, PASI 50, PASI 75 and PASI 90 response rates, percent change from baseline in PASI scores and all other efficacy parameters were similar between the pooled switched and pooled continued treatment groups at all time points. The incidence of treatment-emergent adverse events including injection site reactions was comparable between the pooled switched (36.7%) and pooled continued (34.9%) groups. None of the patients in either treatment group were positive for binding anti-drug antibodies in TP2. CONCLUSION: Treatment efficacy, safety and immunogenicity were similar between the pooled continued and pooled switched treatments during TP2, indicating that there are no effects in the short term on clinical data of multiple switches between GP2015 and ETN.

Comprehensive Center for Inflammation Medicine University Hospital Schleswig Holstein Lübeck Germany

Department of Dermatology Charles University 3rd Medical Faculty and Faculty Hospital Kralovske Vinohrady Prague 10 Czech Republic

Dermatology Centre Salford Royal Hospital University of Manchester Manchester Academic Health Science Centre Manchester UK

Global Clinical Development Biopharmaceuticals Hexal AG Holzkirchen Germany

Psoriasis Center at the Department of Dermatology Universitaetsklinikum Schleswig Holstein Kiel Germany

Zobrazit více v PubMed

Daller J. Biosimilars: a consideration of the regulations in the United States and European union. Regul Toxicol Pharmacol 2016; 76: 199–208. PubMed

USFDA . Scientific considerations in demonstrating biosimilarity to a reference product ‐ Guidance for industry. Last updated on 2015. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm537135.pdf (last accessed on Feb 06, 2017).

European Medicines Agency . Guideline on similar biological medicinal products containing biotechnology‐derived proteins as active substance: non‐clinical and clinical issues. 2014. Last updated on December 18, 2014. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf (last accessed: Feb 06, 2017).

Kay J. Editorial: biosimilars: new or Deja Vu? Arthritis Rheumatol 2016; 68: 1049–1052. PubMed

Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits 2013; 6: 469–478. PubMed PMC

USFDA . Considerations in demonstrating interchangeability with a reference product‐ Guidance for industry. Last updated on 2017. URL http://www.fda.gov/ucm/groups/fdagov‐public/@fdagov‐drugs‐gen/documents/document/ucm537135.pdf (last accessed on Apr 04, 2017).

Kurki P, van Aerts L, Wolff‐Holz E et al Interchangeability of biosimilars: a European perspective. BioDrugs 2017; 31: 83–91. PubMed

Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals (Basel) 2012; 5: 353–368. PubMed PMC

Li EC, Abbas R, Jacobs IA, Yin D. Considerations in the early development of biosimilar products. Drug Discov Today 2015; 20(Suppl 2): 1–9. PubMed

Griffiths CEM, Thaci D, Gerdes S et al The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis. Br J Dermatol 2017; 176: 928–938. PubMed

Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5‐point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2015; 26: 23–31. PubMed

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216. PubMed

Weise M, Bielsky MC, De Smet K et al Biosimilars: what clinicians should know. Blood 2012; 120: 5111–5117. PubMed

de Vries MK, van der Horst‐Bruinsma IE, Nurmohamed MT et al Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 531–535. PubMed

Vincent FB, Morand EF, Murphy K et al Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)‐specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013; 72: 165–178. PubMed

USFDA . Assay development and validation for immunogenicity testing of therapeutic protein products ‐ Guidance for industry. Last updated on 2016. https://www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf (last accessed on Apr 05, 2017).

Poetzl J, Arlt I, von Richter O, Wöhling H, Afonso M and Schaffar G. State‐of‐the‐art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015. J Eur Acad Dermatol Venereol 2017. http://doi.org/10.1111/jdv.14632. PubMed DOI

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study